Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC).

Authors

Ruchit Shah

Pharmerit International, Bethesda, MD

Ruchit Shah , Marc Botteman , Caitlyn Solem , Linlin Luo , Justin Doan , David Cella , Robert J. Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2016 Genitourinary Cancers Symposium

bookmark_border

CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).

First Author: Robert J. Motzer

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Long-term survivorship rates among patients with previously treated advanced renal cell carcinoma receiving nivolumab: Analyses based on ≥ 7 years of follow-up from CheckMate 025 trial.

First Author: Saby George

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.

First Author: Robert J. Motzer

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour?

First Author: Thierry Landre